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A Genome-wide Association Study of 
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Richard M. Turner1,*, Vanessa Fontana1, Jieying E. Zhang1, Daniel Carr1, Peng Yin2,3, Richard FitzGerald1, 
Andrew P. Morris2,4 and Munir Pirmohamed1
Atorvastatin (ATV) is frequently prescribed and generally well  tolerated, but can lead to myotoxicity, especially 
at higher doses. A genome-wide association study of circulating levels of ATV, 2-hydroxy (2-OH) ATV, ATV lactone 
(ATV L), and 2-OH ATV L was performed in 590 patients who had been hospitalized with a non-ST elevation acute 
coronary syndrome 1 month earlier and were on high-dose ATV (80 mg or 40 mg daily). The UGT1A locus (lead single 
nucleotide polymorphism, rs887829) was strongly associated with both increased 2-OH ATV/ATV (P = 7.25 × 10−16) 
and 2-OH ATV L/ATV L (P = 3.95 × 10−15) metabolic ratios. Moreover, rs45446698, which tags CYP3A7*1C, was 
nominally associated with increased 2-OH ATV/ATV (P = 6.18 × 10−7), and SLCO1B1 rs4149056 with increased 
ATV (P = 2.21 × 10−6) and 2-OH ATV (P = 1.09 × 10−6) levels. In a subset of these patients whose levels of ATV and 
metabolites had also been measured at 12 months after hospitalization (n = 149), all of these associations remained, 
except for 2-OH ATV and rs4149056 (P = 0.057). Clinically, rs4149056 was associated with increased muscular 
symptoms (odds ratio (OR) 3.97; 95% confidence interval (CI) 1.29–12.27; P = 0.016) and ATV intolerance (OR 1.55; 
95% CI 1.09–2.19; P = 0.014) in patients (n = 870) primarily discharged on high-dose ATV. In summary, both novel 
and recognized genetic associations have been identified with circulating levels of ATV and its major metabolites. 
Further study is warranted to determine the clinical utility of genotyping rs4149056 in patients on high-dose ATV.
Statins are the cornerstone of cholesterol-lowering pharmaco-
therapy and among the most frequently prescribed medications 
worldwide. Atorvastatin (ATV) is the guideline-recommended 
first-line lipid-lowering drug in primary and secondary prevention 
of cardiovascular disease.1
The metabolism of ATV is shown in Figure 1. Briefly, ATV can 
be hydroxylated by cytochrome P450 3A (CYP3A) to 2-hydroxy 
(2-OH) ATV and 4-OH ATV, or undergo lactonization via an 
unstable acyl glucuronide intermediate to ATV lactone (ATV L).2 
ATV L can be similarly hydroxylated by CYP3A,3 or 2-OH ATV 
and 4-OH ATV conceivably undergo lactonization, producing 
2-OH ATV L and 4-OH ATV L. The lactone metabolites can 
be hydrolyzed via plasma paraoxonases to their corresponding hy-
droxy acids.4
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 There is high interindividual variability in circulating ator-
vastatin (ATV) levels, and higher statin exposure increases the 
risk of statin-related muscle toxicity.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What genomic variants are associated with circulating levels of 
ATV and its metabolites in patients using a genome-wide associa-
tion study, and what is the clinical impact of identified variants?
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 This study found the UGT1A locus to be strongly associ-
ated with ATV disposition. The role of SLCO1B1 rs4149056 
(c.521T>C, p.V174A) on increasing ATV exposure was con-
firmed, and CYP3A7 was newly associated with ATV hy-
droxylation. Patients were primarily on high-dose ATV, and 
SLCO1B1 rs4149065 increased the risk of muscular complaints 
and ATV intolerance.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 The clinical impact of SLCO1B1 rs4149056 in patients on 
high-dose ATV needs further study and, if confirmed, consid-
eration for clinical implementation. Further research is required 
to understand the complex effects of UGT1A on ATV disposi-
tion and to study the influence of CYP3A7 on other CYP3A-
substrate drugs.
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Although generally well tolerated, statins are associated with 
adverse drug reactions in a small subset of patients, including sta-
tin-related myotoxicity (SRM) and new-onset diabetes mellitus.5 
SRM ranges from common muscular symptoms (~  5% patients) 
where causal inference can be challenging to uncommon myopa-
thies (~  0.1%) and, rarely, rhabdomyolysis (0.1–8.4/100,000 pa-
tient-years).5 Risk factors include higher statin dose, comedications 
that inhibit cytochrome P450 3A (CYP3A), and potentially in-
creased circulating levels of statin lactone species, which are consid-
ered more myotoxic.5-7 The solute carrier organic anion transporter 
family member 1B1 gene (SLCO1B1) encodes the hepatic xenobi-
otic influx transporter, OATP1B1. Importantly, a common nonsyn-
onymous variant in SLCO1B1, rs4149056 (c.521T>C, p.V174A), 
is associated with elevated systemic exposure of ATV and all other 
statins except fluvastatin.8 Furthermore, SLCO1B1 rs4149056 has 
been consistently associated with simvastatin-related myotoxicity.7,9
Taking all the evidence together, increased systemic statin expo-
sure seems to predispose to SRM. Therefore, identifying factors that 
alter ATV exposure is important, particularly given the high interin-
dividual variability (45-fold) in circulating ATV levels that has been 
reported.10 Candidate gene studies have reported variants affecting 
ATV pharmacokinetics in ABCG2,11 CYP3A4,12 CYP3A5,12 and 
PPARA,13 but to date no comprehensive genome-wide association 
study (GWAS) has been undertaken. Therefore, the aim of this 
study was to conduct a large GWAS of steady-state plasma levels of 
ATV and its major metabolites in a patient cohort on ATV follow-
ing a recent non-ST elevation acute coronary syndrome (NSTE-
ACS) and to relate the identified variants to clinical outcomes.
METHODS
Pharmacogenetics of acute coronary syndrome study
This investigation utilized the pharmacogenetics of acute coronary 
syndrome (PhACS) study, described previously.14 Briefly, PhACS was 
a UK multicenter prospective observational study that recruited 1,470 
patients hospitalized with an NSTE-ACS. Follow-up was at 1 (visit 2, 
V2) and 12 (V3) months, and annually thereafter until all patients had 
been followed up for at least 12 months. Patient demographics, comor-
bidities, medication information, and biosamples (blood and urine) 
were collected at recruitment; drug use, adherence, new events, and bio-
samples (V2/V3 only), were collected at follow-up. Participants were 
genotyped using the Illumina HumanOmniExpressExome-8 version 
1.0 BeadChip at Edinburgh Genomics (Roslin Institute, Scotland).
The protocol was approved by the Liverpool (adult) research Ethics 
Committee (UK), site-specific approval was granted at all study sites, and 
informed consent was ascertained from all study subjects in accordance 
with the Declaration of Helsinki.
Determination of ATV and metabolite concentrations
The concentrations of ATV and its three major metabolites (2-OH 
ATV, ATV L, and 2-OH ATV L)11 were quantified in EDTA plasma 
Figure 1 Atorvastatin (ATV) biotransformation. ATV can be hydroxylated by cytochrome P450 3A (CYP3A) to 2-hydroxy (2-OH) ATV and 4-OH 
ATV, or undergo lactonization via an unstable acyl glucuronide intermediate to ATV lactone (ATV L).2 The main CYP3A enzyme responsible 
for ATV hydroxylation is CYP3A4 rather than CYP3A5, although CYP2C8 contributes a small amount to ATV 4-hydroxylation in vitro.3 Uridine 
5′-diphospho (UDP)-glucuronosyltransferase (UGT) 1A3 has the highest in vitro rate of ATV lactonization, followed by UGT1A1 and then 
UGT2B7.39 Moreover, ATV L can be hydroxylated by CYP3A, or 2-OH ATV and 4-OH ATV conceivably undergo lactonization, producing 2-OH 
ATV L and 4-OH ATV L. ATV and its hydroxy-metabolites collectively inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) to 
reduce circulating low-density lipoprotein cholesterol. The lactone metabolites are inactive against HMGCR, but can be hydrolyzed via plasma 
paraoxonases (PONs) to their corresponding hydroxy acids.4 The major analytes are underlined and were investigated here.
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samples from V2 (and V3 if eligible—see cohort selection below) using 
a high-performance liquid chromatography-tandem mass spectrometry 
assay developed and validated for this study.15 The dynamic range for 
the analytes was 0.5–125 ng/mL. Briefly, each 50 µL aliquot of partic-
ipant plasma was mixed with 20  µL composite internal standard solu-
tion containing a deuterated internal standard for each analyte, before 
180 µL 100% acetonitrile containing 0.3% acetic acid was added. After 
centrifugation, the supernatant was diluted 1:2 in water and a 5 μL al-
iquot was injected into a 2.7 µm Halo C18 column (50 × 2.1 mm ID, 
90Å; Hichrom Limited, Reading, UK) that separated analytes using 
gradient elution. Analyte detection was via multiple reaction monitoring 
(Sciex triple quadrupole 6500 QTRAP mass spectrometer with a Turbo 
V electrospray source; AB Sciex, Warrington, UK) using transitions (all 
(M + H+) m/z): ATV 559.3 → 440.3, 2-OH ATV 575.3 → 250.2, ATV 
L 541.3 → 276.2, 2-OH ATV L 557.3 → 276.2, ATV-d5 564.1 → 445.1, 
2-OH ATV-d5 580.2  →  255.1, ATV-d5 L 546.3  →  281.2, and 2-OH 
ATV-d5 L 562.2 → 281.1.
GWAS cohort selection and end points
The inclusion criteria for the main cohort used for the GWAS of ATV 
and metabolite levels at V2 were: PhACS participants that had passed 
all genetic quality control (QC; see below) procedures, were taking 
ATV at the same dose of 80 or 40  mg daily at baseline and V2 (so 
steady-state had been reached), and both ATV adherence data and an 
EDTA sample were available at V2. Exclusion criteria were low out-
lier participants with two or more analytes < 0.5 ng/mL (i.e., less than 
the lower limit of quantification), and high outlier participants with 
ATV ≥ 31 ng/mL or ≥ 15.5 ng/mL if prescribed ATV 80 mg or 40 mg, 
respectively.
Participants with 2 or more analytes <  0.5  ng/mL were excluded 
because they were more likely to be statin nonadherent (reported 
missing at least one ATV pill in the previous week) compared with 
those with no low concentrations (P = 0.001). Participants with only 
1 analyte <  0.5  ng/mL seemed similarly statin adherent compared 
with those with no low concentrations (P  =  0.88), could have un-
usual ATV pharmacokinetics, and so were retained. Time since last 
dose was determined by assuming ATV was administered at 22:00 the 
preceding night, because only time of blood sampling was precisely 
known. An approximate time since last dose is a common limitation 
in observational pharmacogenomic studies,16 and this time data can-
not be retrospectively collected. The mean sampling time of 14 hours 
is also on the low curvature aspect of the analyte concentration-time 
profiles17 and so the effect of sampling time measurement error is 
expected to be low.16 Nevertheless, to minimize any high outlier ef-
fect from recent ATV administration, the ceiling of ≥ 31 ng/mL for 
ATV 80  mg was based a priori on mean ATV concentration plus 3 
SDs from a previous smaller study that measured patient ATV lev-
els.10 This ceiling was halved for ATV 40 mg. Accordingly, time since 
last dose was reassuringly strongly associated with ATV levels here 
(P = 4.20 × 10−14).
All eligible participants were included in the main cohort to maximize 
discovery sample size. However, in a subset of these participants (cohort 
2), ATV and metabolite concentrations were also determined at V3 to as-
sess whether biologically plausible variants (see below) identified in the 
main cohort (at V2) remained associated at 12 months. These participants 
were selected if they were on ATV 80 mg daily at V2 and V3, had been 
adherent to ATV 80 mg at V2 and V3, and an EDTA sample was available 
at V3. ATV analyte quantification at V3 was limited to ~ 25% of those in 
the main cohort due to practical constraints. The same exclusion criteria 
were applied to the V3 concentrations as to the V2 concentrations in the 
main cohort.
The GWAS end points were: The individual concentrations of ATV 
and its three metabolites, analyte ratios (hydroxylation—2-OH ATV/
ATV, 2-OH ATV L/ATV L; lactonization—ATV L/ATV), and the sum 
of analytes (ATV + 2-OH ATV + ATV L + 2-OH ATV L) at V2.
Cohort selection and end points for assessment of identified 
variants with clinical outcomes
PhACS participants that had passed genetic QC (see below) and were 
discharged from their baseline NSTE-ACS hospitalization on ATV at 
any dose formed a larger clinical cohort. This cohort was used to inves-
tigate the association between biologically plausible variants and time 
to major adverse cardiovascular (CV) events (MACEs; a composite 
of myocardial infarction, ischemic stroke, or CV death) and all-cause 
mortality (ACM). From this cohort, patients whose statin status (on 
statin or discontinuation), statin prescription, statin adherence, and 
adverse events were all known at V2 were used to assess whether identi-
fied variants were associated with any adverse event reported at V2 and 
attributed by the patient to their statin, and specifically muscular symp-
toms while on statin therapy, and ATV intolerance. ATV intolerance 
was defined as ATV discontinuation, ATV dose reduction, switching 
to a different statin of lower equivalent dose, and/or ATV nonadher-
ence (self-reported missing at least one ATV pill in the last week) at V2.
Statistical analysis
Genetic quality control and imputation. There were 1,442 participants 
successfully genotyped. Per-individual QC was carried out excluding partic-
ipants with genotype call rate < 95% (n = 54), discordant clinical/X-chro-
mosome-derived sex (n = 7), and aberrant heterozygosity (n = 1). For each 
pair of individuals with an identity by descent > 0.1875 using pruned ge-
netic data, the individual with the worse call rate and/or absence of CV 
events during follow-up was removed (n = 5). Potential confounding due 
to population stratification was assessed by principal component (PC) 
analysis (PCA). The reference PCA model was built using international 
HapMap 3 data from European (CEU), Asian (CHB + JPT), and African 
(YRI) ancestry individuals (Figure S1).18 After application of the PCA 
model to PhACS, genetically non-European ancestry participants were ex-
cluded (n = 18), leaving n = 1,357 participants. Per-marker QC excluded 
single nucleotide polymorphisms (SNPs) with call rate < 95%, minor allele 
frequency < 5%, and SNPs deviating from Hardy-Weinberg equilibrium 
(P < 0.0001). QC was carried out in PLINK version 1.07 (http://zzz.bwh.
harva rd.edu/plink /).19 Subsequently, the genotype scaffold was prephased 
using SHAPEIT version 2 (https://mathg en.stats.ox.ac.uk/genet ics_softw 
are/shape it/shape it.html)20 and imputed to the 1000 Genomes Phase I ref-
erence panel (all ancestries, March 2012 release) using IMPUTE2 (http://
mathg en.stats.ox.ac.uk/imput e/impute_v2.html).21 Post-GWAS QC 
excluded SNPs with information score (a measure of imputation quality) 
< 0.4 or minor allele frequency < 1%.
GWAS. The ATV analytes, analyte ratios, and sum total were log10 
transformed to adjust for right skew. Prior to GWAS, multivariable lin-
ear regression was used for covariate selection (Tables S1-S3), as done 
previously with sparse ATV sampling.10 Clinical variables with a univar-
iate P  ≤  0.1 underwent multivariable linear regression modeling using 
stepwise selection to determine the baseline clinical covariate model for 
each end point (P < 0.05 taken to indicate clinical covariate multivari-
able significance). All clinical variables in the main cohort had <  2% 
data missing. The clinical variables selected were very similar to those 
described previously.22 To adjust for fine-scale European ancestry popu-
lation structure, the first two principal components were also included as 
covariates in all GWAS analyses.
For each end point, a GWAS was conducted using frequentist associ-
ation testing assuming an additive model of SNP effect and considering 
genotype dosages within SNPtest version 2.5 (https://mathg en.stats.
ox.ac.uk/genet ics_softw are/snpte st/snpte st.html).23 Manhattan and 
QQ plots were created using the qqman package24 within the R statis-
tical framework25; lambda genomic control inf lation factor was also 
calculated. A Bonferroni multiple testing-corrected genome-wide sta-
tistical significance threshold of P < 5.0 × 10−8/8 tests = 6.25 × 10−9 
was applied.
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Appraisal of genomic signals. Genomic signals were investigated 
using: Regional locus plots (http://locus zoom.sph.umich.edu/),26 
Ensembl Variant Effect Predictor (http://www.ensem bl.org/info/docs/
tools /vep/index.html),27 expression quantitative trait loci (eQTL) using 
the Genotype-Tissue-Expression analysis release V8 (https://www.gtexp 
ortal.org/home/),28 and assessment based on prior knowledge of gene ac-
tion and statin pharmacology. From the above, functional variants with 
biological plausibility were identified. These variants were conditioned 
on, alongside the covariates, and their region re-analyzed within SNPtest 
version 2.5. Lastly, the proportion of observed variability (R2) explained 
by these variants was assessed by multivariable linear regression.
Assessment of biologically plausible variants with analyte lev-
els at 12 months. Identified variants were further assessed by deter-
mining their association to their respective V3 analyte end point(s) by 
multivariable linear regression within cohort 2, adjusted for age, sex, 
time since last V3 ATV dose, and sample storage duration (P < 0.05 
taken to be significant) if included in an end point’s V2 covariate 
model (Table S3).
Sensitivity analysis. A localized chromosome 2 analysis of 2-OH ATV/
ATV was conducted after exclusion of all outlying participants whose 
2-OH ATV/ATV ratio was outside two SDs from the mean to investi-
gate whether the locus signal was attributable to outliers.
Clinical end point analysis. Cox proportional hazards regression was 
used in the clinical cohort to assess the impact of biologically plausible 
SNPs on time to MACE and ACM during all follow-up from baseline 
discharge. For MACE, participants were censored at the earliest of the 
date of non-CV disease death or date of last recorded visit. For ACM, 
participants were censored at the date of the last recorded visit. The 
clinical end points determined at V2 (statin adverse events, muscular 
symptoms, and ATV intolerance) were analyzed by logistic regression. 
In all clinical analyses, if a SNP had univariate P  ≤  0.1, its adjusted 
association was tested by adding it to a multivariable model containing 
clinical covariates (with univariate P ≤ 0.1) that had been chosen by 
forward likelihood ratio selection. SNPs were tested using an additive 
model, considering genotype dosage when necessary. In addition, the 
borderline association between SLCO1B1 rs4149056 and muscular 
complaints was explored further using a dominant model given the 
low number of reported muscle complaints and its role in simvastatin 
myotoxicity.7 The multiple testing-corrected significance threshold 
was P < 0.05/16 tests = 0.003.
The 12 month and clinical analyses were conducted using IBM SPSS 
version 22.0 (IBM, Armonk, NY).
RESULTS
GWAS
Overall, 590 patients were included in the main cohort. The study 
selection process is summarized in Figure 2. In the main cohort, 
77% of patients were men, median age was 64 years old, 551 were 
on ATV 80 mg, and 39 on ATV 40 mg daily. The median con-
centrations of ATV 80 mg and 40 mg were 5.2 and 4.4 ng/mL, 
respectively. The clinical characteristics of the main cohort, and 
clinical variables selected for the analyte multivariable covari-
ate models are in Supplementary Tables S1 and S3, respec-
tively. Following QC, the number of SNPs preimputation and 
postimputation were 598,054 and 8,659,258, respectively. The 
Manhattan plots for ATV, ATV L, 2-OH ATV, and 2-OH ATV 
L are presented in Figure 3, and the plots for 2-OH ATV/ATV, 
2-OH ATV L/ATV L, ATV L/ATV, and the sum of analytes are 
in Figure 4. Importantly, the UGT1A locus (lead SNP, rs887829) 
on chromosome 2 was associated with increased metabolic ratios 
of both 2-OH ATV/ATV (P = 7.25 × 10−16) and 2-OH ATV L/
ATV L (P = 3.95 × 10−15) at genome-wide significance (Figure 4, 
Table 1). The untransformed, unadjusted median 2-OH ATV/
ATV ratio increased from 1.1 to 1.3 to 1.8 in those with none, 1 or 2 
rs887829 minor alleles, respectively. The lead SNP, rs887829, was 
genotyped on the array and its minor allele was an eQTL within 
the Genotype-Tissue-Expression project associated with higher 
UGT1A3 expression and lower UGT1A1 expression in liver, and 
higher UGT1A7 and lower UGT1A6 expression in esophagus mu-
cosa. No other genome-wide significant loci were identified. There 
was no evidence of genomic inflation (Figure S2).
Biologically plausible signals
From the GWAS analysis, three biologically plausible loci were 
identified: the genome-wide significant UGT1A locus, and two 
further loci, SLCO1B1 and CYP3A7, of nominal significance 
(Table 1). Figure 5 shows regional plots of these loci. The full list 
of nominally associated lead SNPs are available in Table S4.
The ATV chromosome 12  lead SNP (rs4363657; 
P  =  1.63  ×  10−6) was in SLCO1B1 and was in linkage disequi-
librium (LD; r2  =  0.70) with the SLCO1B1 missense SNP, 
rs4149056 (p.V174A), known to increase ATV levels17; both 
rs4363657 and rs4149056 were genotyped on the array. The 
rs4149056 minor allele was also nominally associated with higher 
ATV (P = 2.21 × 10−6) and 2-OH ATV (P = 1.09 × 10−6) con-
centrations, but not with ATV L (P = 0.0032) or 2-OH ATV L 
(P  =  0.0042) levels, in keeping with previous healthy volunteer 
results.17 The untransformed, unadjusted median ATV concentra-
tion increased from 4.7 to 6.3 to 10.9 ng/mL in those with none, 1 
or 2 rs4149056 minor alleles, respectively.
The minor allele of a lead chromosome 7 SNP (rs45446698; 
T>G) was nominally associated with increased 2-OH ATV/AVT 
(P = 6.18 × 10−7) and 2-OH ATV L/ATV L (P = 2.91 × 10−5; 
Table 1) ratios. The untransformed, unadjusted median 2-OH 
ATV/ATV ratio increased from 1.2 to 1.8 in those with none or 
one rs45446698 minor allele, respectively; no individual was ho-
mozygous. SNP rs45446698 is an eQTL associated with higher 
CYP3A7 expression in the liver, terminal ileum of the small in-
testine, and adrenal gland.29 Moreover, rs45446698 is one of 
seven correlated SNPs (rs11568824, rs45494802, rs45575938, 
rs45467892, rs11568825, rs11568826, and rs45446698) that clus-
ter within the CYP3A7 promoter and constitute the CYP3A7*1C 
allele, which has been associated with increased adult CYP3A7 
expression.30,31 Although rs45446698 was imputed (info score 
0.93), rs11568824 was genotyped on the array, is in LD with 
rs45446698 (r2  =  0.74), and was also correlated with increased 
2-OH ATV/ATV (P = 1.23 × 10−5) and 2-OH ATV L/ATV L 
(P = 6.31 × 10−5) hydroxylation ratios.
In the sensitivity analysis that excluded patients with outly-
ing 2-OH ATV/ATV ratios, there was minimal impact on the 
rs887829 association signal (P = 7.25 × 10−16 to P = 3.31 × 10−14), 
indicating that the UGT1A signal is not attributable to outliers. 
Conditioning separately on rs4149056 (SLCO1B1), rs45446698 
(CYP3A7), and rs887829 (UGT1A), led to a complete loss of 
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signal for each end point. Inclusion of rs4149056 into the ATV 
model increased the proportion of ATV concentration variance ex-
plained from 16.9% to 20.2%; sequential addition of rs887829 and 
rs45446698 to the 2-OH ATV/ATV multivariable clinical model 
increased variability explained from 15.8% to 25.2% to 28.6%, re-
spectively (Table S5).
Assessment of signals with analyte levels at 12 months
At V3, analyte concentrations from 149 patients were available 
(cohort 2). The associations remained significant for rs887829 
(UGT1A) and rs45446698 (CYP3A7; Table 1). SLCO1B1 
rs4149056 was associated with ATV (P = 0.0082) but not 2-OH 
ATV concentration (P = 0.057; Table 1).
Clinical analyses
The discharge ATV doses and clinical end point constituents 
of the clinical cohort (n  =  1,081) are summarized in Table S6. 
Briefly, 90% of patients were discharged on ATV 80 mg, 7% on 
ATV 40 mg, and the remainder on ATV 10–30 mg. There were 
142 MACE and 93 ACM events. From this cohort, 870 had statin 
status, statin prescription, statin adherence, and adverse events all 
available at V2; of these: 53 reported any adverse event, 13 spe-
cifically muscular complaints, 118 were ATV intolerant, and 752 
ATV tolerant. SLCO1B1 rs4149056 was nominally associated 
with both muscular symptoms (P = 0.016) and ATV intolerance 
(P  =  0.014; Table 2). However, rs4149056 was not associated 
with MACE or ACM, and no association surpassed the multiple 
testing threshold. Neither rs45446698 (CYP3A7) nor rs887829 
(UGT1A) were associated with any clinical end point.
DISCUSSION
The main findings of this study were: Confirmation of the asso-
ciation of rs4149056 (SLCO1B1) with elevated ATV and 2-OH 
ATV systemic levels, identification of rs45446698 (CYP3A7) 
with ATV hydroxylation, and a single strong genome-wide sig-
nificant signal between the UGT1A locus (rs887829) and both 
Figure 2 The study cohort selection process. Time points: DC = discharge from baseline hospitalization for a non-ST elevation acute 
coronary syndrome; V2 = visit 2 (1-month follow-up); V3 = visit 3 (12-month follow-up). The clinical end points of adverse events, muscular 
symptoms, and ATV intolerance required statin status (on statin, or discontinuation), prescription (type of statin, dose), patient-reported 
statin adverse events, and statin adherence to be all known at V2. Low outliers were participants with two analytes < 0.5 ng/mL (lower limit 
of quantification). High outliers were those with ATV ≥ 31 ng/mL (on ATV 80 mg) or ≥ 15.5 ng/mL (ATV 40 mg). MACE/ACM, major adverse 
cardiovascular event/all-cause mortality; QC, quality control.
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2-OH ATV/ATV and 2-OH ATV L/ATV L metabolic ratios. 
The minor allele of rs4149056 was nominally associated with an 
increased risk of muscular symptoms and ATV intolerance.
The minor allele of nonsynonymous SLCO1B1 rs4149056 is 
associated with decreased intrinsic OATP1B1 transport activity, a 
221% increase in area under the simvastatin acid concentration-time 
Figure 3 Manhattan plots of atorvastatin (ATV) and metabolites. Genome-wide association analyses were carried out using log10 transformed 
analyte concentrations in the main cohort, adjusted for the first two principal components and selected clinical covariates (as specified in Table S3), 
by frequentist association testing assuming an additive model of effect and considering genotype dosage. Green dots indicate genotyped variants.
Figure 4 Manhattan plots of atorvastatin (ATV) metabolic ratios and the sum of analytes. Genome-wide association analyses were carried 
out using log10 transformed metabolic ratios or analyte concentrations within the main cohort, adjusted for the first two principal components 
and selected clinical covariates (Table S3), by frequentist association testing assuming an additive model of effect and considering genotype 
dosage. Green dots indicate genotyped variants.
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curve (AUC) in homozygotes, and simvastatin myotoxicity.7,9,32 
Carrying two rs4149056 minor alleles is also associated with 
144% increase in ATV AUC in healthy volunteers.17 However, 
rs4149056 was not significantly associated with ATV myotoxicity 
in a meta-analysis, although fewer participants took ATV relative 
to simvastatin in the included studies.9 Interestingly, the rs4149056 
minor allele has been associated with dose decreases, switching, and 
intolerance primarily to simvastatin (risk estimates 1.74–3.1633,34), 
and potentially in patients on ATV, but only if taking > 20 mg ATV 
daily (hazard ratio 3.26).33 The current study is unusual in primar-
ily investigating high-dose ATV (predominantly 80 mg), and adds 
further support that rs4149056 is associated with ATV intolerance. 
Moreover, statin discontinuation/nonpersistence/nonadherence 
are associated within an increased risk of MACE,35 although no 
association between rs4149056 and MACE or ACM was observed 
here, perhaps due to the limited sample size.
The UGT1A locus at chromosome 2q37.1 contains 13 unique 
first exons, of which 4 are pseudogenes, followed by 4 common 
exons that can be spliced to the 9 functional first exons to give 9 
alternate UGT1A phase II glucuronosyltransferases. The lead 
UGT1A SNP, rs887829, is noncoding and its variant allele has 
been associated in GWAS with elevated circulating bilirubin levels 
and cholelithiasis.36 The variant allele of rs887829 is in tight LD 
with the dinucleotide tandem repeat reduction-of-expression 
UGT1A1*28 allele in white patients,37,38 which underpins 
Gilbert’s syndrome (unconjugated hyperbilirubinemia), irinotecan 
toxicity, and increased risk of jaundice-associated atazanavir dis-
continuation.38 Within the confines of this study, it was, however, 
not possible to genotype UGT1A1*28.
Statin acids are glucuronidated to an unstable acyl glucuronide 
intermediate that undergoes spontaneous cyclization to the corre-
sponding statin lactone.2 In vitro, UGT1A3 has the highest rate 
of ATV lactonization, followed by UGT1A1, whereas UGT2B7 
catalyzes to a minor extent.39 On the other hand, tissue expression 
of UGT1A1 is higher than UGT1A3 in liver and small intestine. 
Furthermore, UGT1A3*2 is in strong LD with UGT1A1*28. 
Thus, in one study, UGT1A1*28 carriers had lower systemic ATV 
L exposure.40 However, another study showed that UGT1A3*2 
is associated with increased hepatic microsomal UGT1A3 pro-
tein levels, increased ex vivo ATV lactonization, and increased 
ATV lactonization in healthy volunteers.41 UGT1A3*2, *3, and 
*6 are haplotypes of rs2008584, rs1983023, and rs45449995, 
which were themselves associated with higher 2-OH ATV/ATV 
(P  =  3.93  ×  10−8, 6.60  ×  10−10 and 5.46  ×  10−5, respectively). 
Figure 5 Regional plots of identified biologically plausible loci. Regional plots showing the SLCO1B1 locus with atorvastatin (ATV) (a), the 
CYP3A locus, including CYP3A7 with 2-OH ATV/ATV (b), and the UGT1A locus with 2-OH ATV/ATV (c), and 2-OH ATV L/ATV L (d). The color of the 
single nucleotide polymorphisms (SNPs) is based on linkage disequilibrium with the named SNP (in purple).
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In exploratory analysis that adjusted for UGT1A3*2, *3, and *6, 
the signal was attenuated but not extinguished (rs887829 P value 
from 7.25 × 10−16 to 9.96 × 10−7 for 2-OH ATV/ATV), suggest-
ing that UGT1A variants beyond common UGT1A3 haplotypes 
and UGT1A1*28 may also be involved.
Overall, the reason for the association here between rs887829 
and increased hydroxylation, and not lactonization, is unclear. 
Interestingly, observed hydroxylation ratios for ATV and ATV 
L seem increased in UGT1A3*2 carriers compared with wild-
type healthy volunteers following ATV dosing.42 Taking all the 
evidence together, reduced ATV lactonization with increased 
direct hydroxylation of ATV in rs887829 carriers seems per-
haps less likely than increased ATV lactonization, with sub-
sequent increased hydroxylation to 2-OH ATV L (and then 
higher 2-OH ATV levels following hydrolysis). The increased 
hydroxylation in the latter hypothesis is suggested by the rate 
of CYP-dependent metabolism of ATV L being 83-fold higher 
than for ATV.3 However, further metabolic investigations will 
be required.
This, to the best of our knowledge, is the first patient study 
to implicate CYP3A7 in ATV metabolism by associating the 
rs45446698 minor allele with increased ATV hydroxylation. 
ATV is likely a CYP3A7 substrate43 and has been shown in 
vitro to upregulate CYP3A7 protein expression.44 Although 
the rs45446698 signal did not reach genome-wide significance 
(P  =  6.18  ×  10−7 for 2-OH ATV/ATV), it was also signifi-
cant in the analysis of 12-month analyte levels (P  =  0.0010). 
Neither of the common established reduction-of-function alleles, 
CYP3A4*22 (rs35599367) and CYP3A5*3 (rs776746), were in 
LD with rs45446698. Although CYP3A4*22 was marginally as-
sociated with lower ratios of 2-OH ATV/ATV (P = 0.016) and 
2-OH ATV L/ATV L (P  =  0.005), it was not associated with 
ATV or ATV L concentrations; CYP3A5*3 was not associated 
with the end points.
The human CYP3A subfamily consists of CYP3A4, 3A5, 
3A7, and 3A43 located on chromosome 7q22.1.45 CYP3A7 
is the predominant CYP in fetal liver, accounting for 30–50% 
of total fetal liver CYP content.46 However, the majority of 
total adult liver CYP3A content is CYP3A4.45 Nevertheless, 
human liver CYP3A7 mRNA expression varies >  700-fold,47 
and in ~ 10% of adult livers, CYP3A7 is present and contrib-
utes 9–36% of total CYP3A protein content.48 In CYP3A7*1C, 
~ 60 bp of the fetal CYP3A7 promoter region is replaced by the 
corresponding region of the adult CYP3A4 promoter.49 Thus, 
CYP3A7*1C is associated with increased CYP3A7 mRNA ex-
pression in liver and intestine,47 and likely higher liver protein 
levels.48 Sequencing has previously confirmed that rs45446698 
effectively tags CYP3A7*1C.31 Clinically, rs45446698 is asso-
ciated with progesterone and dehydroepiandrosterone sulphate 
levels.50 Moreover, CYP3A7*1C has been associated with in-
creased breast cancer mortality, all-cause mortality in lung can-
cer, and chronic lymphocytic leukemia progression, potentially 
due to increased metabolic deactivation of CYP3A-substrate 
chemotherapeutics.31 Given that ~ 30% of clinically used drugs 
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Study limitations
This study represents the first GWAS of ATV and metabolite levels. 
It was undertaken in a real-world patient cohort, and assessed the 
clinical impact of identified variants. However, external replication 
of the novel findings is required. Studies in patients of non-Euro-
pean ancestry are also required to determine generalizability. Genes 
with a recognized role in drug pharmacokinetics were focused on; 
thus, novel genes of nominal significance may have been detected 
(Table S4), but require functional characterization. Lastly, few pa-
tients self-reported muscular complaints and the etiology of muscu-
lar symptoms is difficult to establish; therefore, caution is required 
when interpreting the muscular symptoms analysis. Nevertheless, 
rs4149056 was also associated with ATV intolerance.
CONCLUSION
In summary, this GWAS has reaffirmed the impact of rs4149056 
(SLCO1B1) on increasing ATV exposure and may also influ-
ence ATV intolerance and muscular complaints in patients on 
high-dose ATV. We have shown that UGT1A seems to be im-
portant in complex pathways associated with ATV disposition, 
whereas CYP3A7 has newly been associated with increased ATV 
hydroxylation.
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